Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Rating of “Moderate Buy” by Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has earned an average rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $5.67.

Separately, HC Wainwright decreased their target price on Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 1st.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $1.09 on Friday. The stock has a market cap of $125.42 million, a PE ratio of -0.89 and a beta of 0.03. Karyopharm Therapeutics has a twelve month low of $0.62 and a twelve month high of $4.09. The stock has a fifty day simple moving average of $1.33 and a 200-day simple moving average of $1.05.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, February 29th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $33.75 million during the quarter, compared to analysts’ expectations of $33.50 million. During the same quarter last year, the firm posted ($0.43) earnings per share. Research analysts predict that Karyopharm Therapeutics will post -1.19 EPS for the current year.

Insider Buying and Selling at Karyopharm Therapeutics

In other Karyopharm Therapeutics news, CEO Richard A. Paulson sold 80,470 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $1.17, for a total value of $94,149.90. Following the sale, the chief executive officer now owns 1,183,783 shares of the company’s stock, valued at approximately $1,385,026.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Michael Mason sold 27,687 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $1.17, for a total value of $32,393.79. Following the transaction, the chief financial officer now owns 404,918 shares in the company, valued at approximately $473,754.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Richard A. Paulson sold 80,470 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $94,149.90. Following the completion of the transaction, the chief executive officer now owns 1,183,783 shares in the company, valued at approximately $1,385,026.11. The disclosure for this sale can be found here. Insiders have sold 171,331 shares of company stock valued at $206,118 in the last quarter. Corporate insiders own 3.32% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Bleakley Financial Group LLC purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at about $33,000. Simplicity Solutions LLC purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at about $33,000. Simplicity Wealth LLC purchased a new position in Karyopharm Therapeutics during the 1st quarter worth approximately $66,000. Wade G W & Inc. purchased a new position in Karyopharm Therapeutics during the 3rd quarter worth approximately $60,000. Finally, SG Americas Securities LLC grew its stake in Karyopharm Therapeutics by 295.0% during the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock worth $64,000 after buying an additional 54,839 shares during the last quarter. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).